Biotest is a company specialising in innovative hematology and immunology products with the holistic approach of a global pharmaceutical, diagnostics and biotherapeutics group. Its approximately 2,000 employees develop, manufacture and sell medicinal products for the treatment of blood and immune diseases as well as products for the hygiene monitoring of air and work surfaces. The most important starting material for our pharmaceutical products is human blood plasma which we process into effective and highly pure medicinal products in one of the world’s most modern production facilities in Europe. Our products are used in the treatment of life-threatening diseases such as coagulation disorders (haemophilia), severe infections or disorders of the immune system. One of our highest priority research projects is the development of monoclonal antibodies, active substances produced by biotechnological techniques, which will open up new prospects in the treatment of rheumatism, leukaemia and other autoimmune diseases. Biotest products meet the highest standards and are sold in markets which have to satisfy the most stringent registration requirements in the world. Patients, hospitals, medical practices, laboratories and companies in 159 countries around the globe put their trust in Biotest’s quality and safety.
Company Growth (employees)
Dreieich, DE
Size (employees)
2,547 (est)+3%
Biotest was founded in 1946 and is headquartered in Dreieich, DE

Biotest Office Locations

Biotest has an office in Dreieich
Dreieich, DE (HQ)
5 Landsteinerstraße

Biotest Financials and Metrics

Biotest Financials


Market capitalization (30-Oct-2017)

983.7 m

Closing share price (30-Oct-2017)

Biotest's current market capitalization is €983.7 m.
Show all financial metrics

Biotest Operating Metrics

FY, 2016

Projects in R&D Pipeline


Phase III Trials

Show all operating metrics

Biotest Market Value History

Biotest's Web-traffic and Trends

Biotest Company Life and Culture

You may also be interested in